Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ResMed completes enrolment of Serve-HF trial

ResMed completes enrolment of Serve-HF trial

4th September 2013

ResMed has announced the completion of enrolment for Serve-HF, the world's largest study of sleep-disordered breathing in heart failure.

The international, randomised study began in 2008 and has recruited 1,325 participants and aims to investigate if the treatment of central sleep apnoea can improve survival rates and outcomes among patients with stable heart failure.

When results from the study are published in 2016, it will provide conclusive evidence of the health impact of effectively treating heart failure patients who have sleep-related breathing problems.

Around 14 million people in Europe are living with heart failure, with central sleep-disordered breathing known to be a highly prevalent comorbidity.

Co-principal investigator Professor Martin Cowie of the Royal Brompton Hospital said: "We now look forward to results in 2016 and to a fuller understanding of just how important the treatment of central sleep-disordered breathing is in heart failure patients."

This comes after the firm recently announced a record-breaking financial performance for the 2012-13 fiscal year.ADNFCR-8000103-ID-801633549-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.